LIG4 and neoplasm: Another strategy to increase tumor sensitivity to DNA damaging agents is to interfere DSBs repair pathways via the use of selective inhibitors of PARP superfamily (e.g. Niraparib, Olaparib), DNA-PKcs (e.g. NU7441, M3814 or Nedisertib, AZD7648, M9831 or VX-984, KU-0060648), CHK1 (e.g. GDC-0575, MK-8776, Prexasertib), ATM (AZD0156, M3541), ATR (Ceralasertib, Berzosertib), WEE1 (Adavosertib) and DNA ligase IV (SCR7, NU7026) (24, 25).